Public Release: 16-Aug-2016 NIH explores connection between Ebola survival and co-infection with malaria parasites NIH/National Institute of Allergy and Infectious Diseases People infected with Ebola virus were 20 percent more likely to survive if they were co-infected with malaria-causing Plasmodium parasites, according to data collected at an Ebola diagnostic laboratory in Liberia in 2014-15. Moreover,…
Public Release: 16-Aug-2016 NIH explores connection between Ebola survival and co-infection with malaria parasites NIH/National Institute of Allergy and Infectious Diseases People infected with Ebola virus were 20 percent more likely to survive if they were co-infected with malaria-causing Plasmodium parasites, according to data collected at an Ebola diagnostic laboratory in Liberia in 2014-15. Moreover,…
MK-4482 shows potential to prevent and treat SARS-CoV-2 infection.
This scanning electron microscope image shows SARS-CoV-2 (orange) also known as 2019-nCoV, the virus that causes COVID-19 isolated from a patient in the U.S., emerging from the surface of cells (gray) cultured in the lab. NIAID
What
The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from National Institutes of Health scientists. SARS-CoV-2 is the virus that causes COVID-19. MK-4482, delivered orally, is now in human clinical trials. Remdesivir, an antiviral drug already approved by the U.S. Food and Drug Administration for use against COVID-19, must be provided intravenously, making its use primarily limited to clinical settings.